滚动资讯
FierceBiotechBeyond the Hype: Turning NAMs into Actionable EvidenceFierceBiotechRevolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trialFierceBiotechAbbVie inks $745M deal with Chinese biotech Haisco for two acute pain assetsFierceBiotechSpyre points to phase 2 win for ulcerative colitis drug as proof it could take on Takeda’s EntyvioBioPharma DiveRevolution pancreatic cancer drug nearly doubles survival in key trialThermo FisherThermo Fisher Scientific’s PPD Clinical Research Business Collaborates with HealthVerity to Expand R - PharmiWeb.comEndpoints NewsAllogene’s first cut of data on ‘off-the-shelf’ CAR-T shows promiseEndpoints NewsNeomorph raises $100M for molecular glues; Spyre's ulcerative colitis dataBioWorldBiggest gainers and losers for April 6-10, 2026Endpoints NewsRegeneron wades into radiopharma through $40M upfront deal with TelixEndpoints NewsBioNTech's HER2 ADC succeeds in Phase 2 study, FDA filing plannedThermo FisherSmall Molecule Innovator API CDMO Market Outlook, 2026-2033 - Lonza Group, Novo Holdings (Catalent) and Thermo Fisher Scientific Lead the Growing Industry - Yahoo Finance UK
FierceBiotech 2026年2月26日

勃林格殷格翰与英国生物科技公司达成5亿美元协议，开发口服自身免疫疾病疗法。

勃林格殷格翰与英国生物科技公司达成5亿美元协议，开发口服自身免疫疾病疗法。

原文
暂时没有全文，请查看原始来源。

目录

59 全部